Vascular Access Device Market Size, Share & Trends Analysis Report By Product Type (Central Vascular Access Devices, Peripheral Vascular Access Devices, Intraosseous Vascular Access Devices, Accessories), By Application (Drug Administration, Fluid & Nutrient Administration, Blood Transfusion, Diagnostics & Testing, Hemodialysis, Chemotherapy, Anesthesia, IV Fluids), By End User (Hospitals, Clinics & Ambulatory Care Centres, Long-Term Care Facilities (LTCFs), Home Healthcare Settings), By Material (Polyurethane, Polyethylene, Teflon, Silicone) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Vascular Access Device Market Size

The global vascular access device market size was valued at USD 6.9 billion in 2024 and is projected to grow from USD 7.3 billion in 2025 to USD 13.8 billion in 2033, exhibiting a CAGR of 7.8% during the forecast period (2025–2033).

The global vascular access device market is experiencing significant growth, driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and end-stage renal disease (ESRD). The rising geriatric population, more susceptible to these conditions, further fuels the demand for vascular access devices. Technological advancements, including the integration of antimicrobial coatings and real-time imaging guidance, enhance the safety and efficacy of these devices, promoting their adoption in clinical settings.

Moreover, the shift towards minimally invasive procedures and expanding home healthcare services contributes to market growth. However, challenges like the risk of catheter-related bloodstream infections (CRBSIs) and the high cost of advanced devices may hinder market expansion. Nonetheless, ongoing research and development efforts to improve device design and functionality are expected to create new opportunities in the market.

Vascular Access Device Market Trend

Integration of artificial intelligence (AI) in vascular access devices

The integration of AI into vascular access devices is revolutionising patient care by enhancing precision and reducing complications. AI-driven systems assist clinicians in real-time decision-making, analysing patient-specific data to optimise catheter placement and minimise risks such as infections and thrombosis. AI algorithms can predict the optimal catheter size and insertion site based on individual patient anatomy and condition.

• For instance, Teleflex introduced the next-generation Arrow™ VPS Rhythm™ DLX Device and NaviCurve™ Stylet in October 2024, engineered to enhance peripherally inserted central catheter (PICC) insertion procedures and reduce complications.

These advancements streamline the insertion process and align with the broader trend of precision medicine, aiming to tailor treatments to individual patient needs. As healthcare systems prioritise patient safety and cost-effectiveness, the adoption of AI in vascular access procedures is expected to grow significantly.

Vascular Access Device Market Driver

Rising prevalence of chronic diseases

The escalating incidence of chronic diseases such as cancer, diabetes, and end-stage renal disease (ESRD) is a primary driver of the market. Patients with these conditions often require long-term intravenous therapies, necessitating reliable vascular access solutions. According to the World Health Organisation (WHO), global cancer cases are expected to rise by over 75% by 2050, reaching more than 35 million new cases annually.

• In the United States, the Centers for Disease Control and Prevention (CDC) reported in May 2024 that more than 1 in 7 adults—about 35.5 million people—are estimated to have chronic kidney disease (CKD). These statistics underscore the growing demand for vascular access devices to facilitate treatments like chemotherapy and dialysis.

Moreover, the ageing global population further amplifies this demand, as older individuals are more susceptible to chronic ailments requiring vascular interventions. Consequently, the market is poised for sustained growth, driven by the need to support an expanding patient population with chronic health conditions.

Market Restraining Factors

Risk of catheter-related bloodstream infections (CRBSIs)

Despite the benefits of vascular access devices, the risk of catheter-related bloodstream infections (CRBSIs) remains a significant restraint in the market. CRBSIs can lead to severe complications, prolonged hospital stays, and increased healthcare costs. The Centers for Disease Control and Prevention (CDC) estimates that approximately 250,000 CRBSIs occur annually in the United States alone. These infections are often associated with improper catheter insertion techniques, inadequate maintenance, and prolonged device use.

To mitigate this risk, healthcare providers must adhere to strict infection control protocols, and manufacturers focus on developing devices with antimicrobial properties and improved materials. However, the persistent threat of CRBSIs continues to challenge the widespread adoption of vascular access devices.

Market Opportunity

Expansion in emerging markets

Emerging markets continue to present substantial growth opportunities for the vascular access device industry, driven by increasing healthcare investments, rising prevalence of chronic diseases, and improving healthcare infrastructure. 

• For example, in January 2025, Stryker Corporation announced a $4.9 billion acquisition of Inari Medical, which specialises in venous thromboembolism treatment products. This strategic move aims to expand Stryker's presence in the vascular access market, particularly in emerging economies where the demand for advanced medical devices is surging. 

Countries like India are witnessing rapid growth in the vascular access devices market in the Asia-Pacific region. This growth is attributed to increasing healthcare expenditure, rising awareness of advanced medical technologies, and a growing patient population requiring long-term intravenous therapies. Manufacturers capitalise on these opportunities by expanding their operations and tailoring products to meet regional needs. Companies like BD and Teleflex are investing in research and development to introduce innovative vascular access solutions suitable for emerging markets. These strategic initiatives are expected to drive the adoption of vascular access devices, enhance patient care, and support the overall market growth in these regions.

Regional Insights

North America holds the largest share of the global vascular access device market, driven by advanced healthcare infrastructure, high prevalence of chronic diseases, and significant investments in research and development. The United States, in particular, contributes substantially to this dominance, with a large patient population requiring vascular access for treatments such as chemotherapy, dialysis, and long-term medication administration. According to the National Cancer Institute, approximately 2,001,140 new cancer cases were projected in the U.S. in 2024, indicating a substantial demand for vascular access devices. The presence of key market players and continuous technological advancements have also contributed to the region's leading position in the market.

U.S. Vascular Access Device Market Trend

• The United States is the largest and most mature market for vascular access devices, fueled by a high prevalence of chronic illnesses such as cancer, kidney disease, and diabetes. Advanced healthcare infrastructure, favourable reimbursement policies, and widespread adoption of new technologies ensure robust demand. The presence of key players like BD, Teleflex, and ICU Medical, along with heavy R&D investments, further strengthens the market. Regulatory bodies like the FDA support innovation in device safety and efficiency, while the shift toward home healthcare and outpatient services continues to expand opportunities for vascular access solutions.
• Canada’s vascular access device market is experiencing steady growth, supported by a strong public healthcare system, an ageing population, and government efforts to minimise hospital-acquired infections. The country’s emphasis on preventive care and chronic disease management has increased the adoption of advanced vascular access devices with antimicrobial coatings and safety features. Supportive policies by Health Canada and growing partnerships with device manufacturers enhance access to innovative medical technologies. Additionally, collaborations with provincial health authorities to improve patient safety outcomes further contribute to expanding this market.

Asia-Pacific Vascular Access Device Market Trend

The Asia-Pacific region is poised to experience the fastest growth in the market for vascular access device, driven by expanding healthcare infrastructure, increasing healthcare expenditure, and a rising burden of chronic diseases. Countries like China, India, and Japan are witnessing a surge in demand for vascular access devices due to their large populations and growing prevalence of conditions requiring long-term intravenous therapies. Furthermore, government initiatives to improve healthcare access and invest in medical infrastructure have created a conducive environment for market growth. The increasing adoption of home-based healthcare services and the rising awareness of advanced medical treatments are also contributing to the rapid expansion of the vascular access device market in the Asia-Pacific region.

• China represents one of the fastest-growing markets for vascular access devices due to its expanding middle class, rising chronic disease prevalence, and government healthcare reforms. The “Healthy China 2030” initiative aims to modernise healthcare infrastructure, pushing hospitals and clinics to adopt advanced medical technologies. Domestic and international manufacturers are increasing investments to localise production and meet growing demand. The surge in chemotherapy, dialysis, and infusion therapies has necessitated more efficient and safer vascular access solutions. China’s growing private hospital network and telemedicine expansion are accelerating adoption, especially in urban centres.
• India’s vascular access device market is expanding rapidly, driven by rising healthcare awareness, increasing patient volumes, and government programs like Ayushman Bharat aimed at improving access to quality care. With a growing burden of non-communicable diseases, especially cancer and kidney failure, the need for long-term intravenous therapies is surging. Public-private partnerships and foreign investments enhance device availability across urban and semi-urban areas. The growth of medical tourism and the shift toward day-care procedures and home infusion therapies also support increased use of vascular access devices in public and private hospitals.

Europe Vascular Access Device Market Trend

Europe represents a significant market for vascular access device, characterised by a well-established healthcare system, increasing healthcare expenditure, and a growing ageing population. Countries such as Germany, the United Kingdom, and France are at the forefront of market growth, driven by the rising incidence of chronic diseases and the adoption of advanced medical technologies. Government initiatives to improve healthcare infrastructure and promote early disease detection have further fueled the demand for vascular access devices in the region. Additionally, collaborations between European healthcare institutions and medical device manufacturers have facilitated the development and adoption of innovative vascular access technologies.

• The United Kingdom is witnessing a rising demand for vascular access devices due to its ageing population and the growing burden of chronic diseases. NHS-led initiatives focusing on reducing hospital stays and promoting home-based care are increasing the need for reliable, long-term vascular access. The adoption of minimally invasive techniques and safer insertion technologies has gained traction in clinical settings. Furthermore, investments in digital health and medical innovation are encouraging market growth. Collaborations between public hospitals and private players enhance accessibility to cutting-edge vascular solutions.
• Germany remains a leading market for vascular access devices in Europe, supported by one of the world’s most advanced healthcare systems. The country's high focus on patient safety, early disease detection, and healthcare digitisation fosters demand for high-quality vascular access technologies. Germany’s industrial strength and homegrown medtech companies, such as B. Braun and Fresenius, contribute to robust domestic manufacturing and innovation. The national emphasis on integrating antimicrobial and biocompatible materials into vascular devices supports infection prevention efforts, a major driver amid the rise of hospital-acquired complications.

Product Type Insights

Central Vascular Access Devices (CVADs) dominate the market due to their extensive use in long-term intravenous therapies such as chemotherapy, parenteral nutrition, and hemodialysis. The increasing prevalence of chronic diseases necessitating prolonged treatment regimens has propelled the demand for CVADs. Furthermore, advancements in catheter materials and insertion techniques have improved patient outcomes and reduced complications, reinforcing the preference for CVADs in clinical settings. The integration of ultrasound-guided insertion methods has enhanced the safety and efficacy of CVAD placement, contributing to their widespread adoption. As healthcare providers prioritise patient comfort and treatment efficiency, the demand for CVADs is expected to maintain its upward trajectory.

Application Insights

Drug administration is the leading application segment in the market, driven by the necessity for efficient and reliable delivery of medications in various therapeutic areas. Vascular access devices facilitate the administration of chemotherapeutic agents, antibiotics, analgesics, and other critical medications, ensuring rapid onset of action and optimal therapeutic outcomes. The growing incidence of chronic diseases, such as cancer and cardiovascular disorders, has intensified the need for long-term intravenous drug delivery systems. Moreover, the shift towards outpatient care and home-based infusion therapies has further amplified the demand for user-friendly vascular access solutions, propelling the growth of this application segment.

End User Insights

Hospitals represent the largest end-user segment in the market, attributed to the high volume of surgical procedures, emergency admissions, and inpatient treatments requiring vascular access. The presence of skilled healthcare professionals and advanced medical infrastructure in hospital settings ensures the safe insertion and management of vascular access devices. Additionally, hospitals often serve as primary centres for administering complex therapies, such as chemotherapy and dialysis, necessitating central and peripheral vascular access devices. Collaborations between hospitals and government bodies for disease awareness campaigns and funding programs have also contributed to the expansion of this segment.

Material Insights

Polyurethane has emerged as the dominant material in the market, owing to its favourable properties such as biocompatibility, flexibility, and durability. These characteristics make polyurethane an ideal choice for manufacturing catheters that can withstand prolonged use without causing irritation or adverse reactions. The material's versatility allows for producing devices suitable for various applications, including central and peripheral vascular access. Furthermore, polyurethane's cost-effectiveness and ease of manufacturing have encouraged its widespread adoption among medical device manufacturers. As the demand for long-term vascular access solutions continues to rise, the preference for polyurethane-based devices is expected to persist, driving the growth of this material segment.

Company Market Share

The global vascular access device market is highly competitive, with several key players striving to maintain their market positions through product innovation, strategic partnerships, and mergers and acquisitions. Companies focus on developing advanced vascular access devices that improve patient outcomes and reduce complications. The competitive landscape is characterised by the presence of both established players and emerging companies, contributing to the market's dynamic nature.

Becton, Dickinson and Company (BD): Becton, Dickinson and Company (BD) maintains its dominant position in the global market. The company's strong geographic presence across 61 countries and a comprehensive product portfolio contribute to its market leadership. BD's commitment to research and development has led to the introduction of innovative vascular access devices, enhancing patient outcomes and safety. The company's strategic acquisitions, such as the acquisition of C.R. Bard in 2017, have further strengthened its market position.

Recent Development

• January 2025- Stryker announced its acquisition of Inari Medical for $4.9 billion. Inari specialises in devices that treat venous diseases such as venous thromboembolism. This acquisition enhances Stryker's portfolio in providing treatments for peripheral vascular diseases.
• June 2024- Boston Scientific agreed to acquire Silk Road Medical, a company specialising in stroke prevention technology, for approximately $1.26 billion. This acquisition will expand Boston Scientific’s vascular portfolio with Silk Road’s minimally invasive transcarotid artery revascularisation technology.